-
Oppenheimer Starts Theravance Biopharma (TBPH) at Outperform
-
Theravance Biopharma (TBPH) Tops Q3 EPS by 20c, provides guidance
-
Theravance Biopharma to present YUPELRI data at CHEST 2025 meeting
-
Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
-
FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
-
B.Riley Starts Theravance Biopharma (TBPH) at Buy
-
BTIG Reiterates Buy Rating on Theravance Biopharma (TBPH)
-
Theravance Biopharma (TBPH) PT Raised to $13 at Leerink Partners
-
Theravance Biopharma (TBPH) Tops Q2 EPS by 41c, provides guidance
-
Theravance Biopharma (TBPH) PT Raised to $25 at BTIG
-
Theravance Biopharma (TBPH) Announces Approval of YUPELRI by China's NMPA
-
BTIG Reiterates Buy Rating on Theravance Biopharma (TBPH)
-
Theravance Biopharma (TBPH) Sells Remaining Royalty Interest in Trelegy Ellipta to GSK (GSK) for $225M
-
Theravance Biopharma (TBPH) Misses Q1 EPS by 5c, Beats on Revenue
-
Theravance Biopharma (TBPH) PT Raised to $24 at BTIG
-
Theravance Biopharma (TBPH) Misses Q4 EPS by 11c ; Provides Outlook
-
H.C. Wainwright Reiterates Buy Rating on Theravance Biopharma (TBPH)
-
Leerink Partners Reiterates Market Perform Rating on Theravance Biopharma (TBPH)
-
Theravance Biopharma (TBPH) Misses Q3 EPS by 3c, provides guidance
-
Theravance Biopharma (TBPH) Announces Publication of YUPELRI Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease
-
H.C. Wainwright Reiterates Buy Rating on Theravance Biopharma (TBPH)
-
Theravance Biopharma (TBPH) PT Lowered to $9 at TD Cowen
-
Theravance Biopharma (TBPH) PT Lowered to $15 at H.C. Wainwright
-
Theravance Biopharma (TBPH) Misses Q2 EPS by 13c, provides guidance

